ArticleEULAR rheumatology open2026
EGPAware: a European Delphi consensus study on red flags for suspicion of eosinophilic granulomatosis with polyangiitis.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Diagnosing eosinophilic granulomatosis with polyangiitis (EGPA) is challenging due to its rarity, multisystem involvement, and varied clinical presentation, often resulting in delayed diagnoses and associated complications. EGPAware project aimed to establish a first European Delphi consensus on red flags for raising suspicion of EGPA to assist the prompt identification, referral, and diagnosis of these patients. Methods: EGPAware was a European Delphi study led by a multidisciplinary committee that developed the survey based on the red flags from a previously published Spanish systematic review and focused on clinical suspicion indicators. Data analysis used descriptive statistics, with consensus defined as ≥70% agreement. Statements with <70% consensus in the first round were revisited again in round 2. In the second round, panellists additionally ranked the 10 most relevant red flags by clinical importance and frequency of observation. Results: A multidisciplinary European group of 53 physicians with expertise in EGPA completed the 2-round Delphi survey. Consensus was reached on 25 red flags. Mononeuritis multiplex, lung infiltrates/nodules, vasculitis on biopsy, and myeloperoxidase-antineutrophil cytoplasmic antibodies positivity were the highest-ranked signs based on clinical relevance, whereas lung infiltrates/nodules, nasal polyposis, and mononeuritis multiplex were most frequently observed in panellists' experience. Conclusions: The EGPAware study provides a useful checklist of consensual red flags to be used in clinical practice to help clinicians identify patients with EGPA early. The study supports a multidisciplinary approach to EGPA diagnosis and management. Further research is recommended to refine diagnostic tools and validate these findings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.